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Therapy

Prehospital Care of Acute Myocardial Infarction: A Review
Asit R. Gokli, MD,* Jay L. Kovar, MD,* Terry Kowalenko, MD,* and
Richard M. Nowak, MD*
Each year more than 1 million people in the Uniled States suffer from acute myocardial infarction
(Ml) with most ofthe deaths occurring within hours of symptom onset. Over the last 25 years, different
prehospital systems have evolved throughout the world which allow early cardiac monitoring and
treatment of acute Ml patients. Thrombolytic therapy in acute Ml has heen shown to decrease
mortality and preserve left ventricular function when administered early after onset of symptoms. The
potential role of Emergency Medical Services or Mohile Coronary Care Units in achieving early
thrombolysis is under investigation. Several studies of prehospital interventions to achieve early
thrombolysis are reviewed. The use of thrombolytics by prehospital personnel has been found to he
feasible, safe, and effective in reducing time delays. However, whether this translates into clinical
benefit remains to he seen. (Heniy Ford Hosp Med J1991:39:170-5)

M

yocardial infarction (MI) affects more than 1 million people per year in the United States and accounts for over
25% of overall annual deaths (1). Most deaths from acute M l occur shortly after the onset of symptoms and therefore outside of
the hospital (2). Recognition of this has led to the development
of efficient prehospital care over the last 25 years which has
proved to be lifesaving in terms of treating chest pain and serious dysrhythmias with medicafions and defibrillafion.
Over the last decade it has become known that early lysis of
an occluding thrombus in the setfing of an acute M I results in
improved left ventricular (LV) function (3-6), reduction in immediate mortality (7,8), and enhancement of long-term survival
(9,10). This has renewed medical interest in the prehospital care
of acute M I . Several studies are under way to better define the
role of prehospital care of acute M I . The important questions to
be answered are: Should thrombolytic therapy be begun in the
prehospital setfing? Is it feasible, safe, and effective? How can
prehospital care of acute M I contribute to early diagnosis and
the decision to use thrombolyfic therapy?

Developments in Prehospital Care
of Acute MI in the United States
The standardization of prehospital emergency medical services (EMS) is a relatively new component of health care. A l though the roots of prehospital care date back to military campaigns in the 18th century and hospital transport in the 1860s,
prehospital services did littie to provide therapeutic interventions and reduce mortality and morbidity until the mid 1960s.
In 1967, in Belfast, Northem Ireland, the first mobile coronary care unit (MCCU) was established. Utilizing cardiac moni-
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tors and defibrillation capabilities, the Belfast group showed
positive benefits by prompt and skillful treatment early in the
course of acute M I before the patient reached the critical care
unit (CCU) in the hospital (11).
Over the years, the administration of antiarrhythmic agents
and defibrillation have become well established prehospital interventions. Early defibrillation has been shown to be the single
most beneficial prehospital intervention (12). However, the benefits of early prehospital care of acute M I are multifactorial.
These include: 1) relief of chest pain; 2) cardiac monitoring for
early recognition and prompt treatment of dysrhythmias by
pharmacologic agents, defibrillation, and electrical cardiac pacing; and 3) control of blood pressure and heart rate (2). Treatment of autonomic dysfunction (hypotension and bradycardia)
associated with acute M I in the prehospital setting has been
shown to decrease ultimate mortality and morbidity (13). Besides decreasing mortality, effective, early prehospital care may
also prevent extension of M I and the later development of pump
failure (2).
Different systems have evolved throughout the world over
the last 25 years to treat acute M l during the prehospital phase.
In the United States, mobile coronary care has largely been incorporated into the EMS system which is staffed by emergency
medical technicians (EMTs) and paramedics (EMTs with specialized training including advanced cardiac life support and an
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upgraded level of skills). Timely assessment and therapeutic intervention, not limited to resuscitation, includes treatment of
secondary complications of acute MI such as hypotension, hypoxia, bradycardia, pulmonary edema, ventricular fibrillation,
and cardiac arrest (14). Thus, in the United States, prehospital
care of acute MI is provided by paramedics or EMTs or a combination of both.
Recent advances in thrombolytic therapy in acute MI and its
time-dependent character have led to a new emphasis on the prehospital care of acute MI.

Historical Review of Thrombolytics in Acute MI
Acute transmural MI is a thrombotic process (15). Coronary
artery thrombus causing total occlusion of the infarct-related
vessel is present in 80% to 90% of patients with acute Ml. In
about 15% to 20% of patients, an intraluminal thrombus is present which causes subtotal occlusion of the infarct-related vessel.
DeWood et al (16), performing cardiac catheterization and
coronary angiograms in 210 Ml patients wilhin 6 hours of the
onset of symptoms, found that 87% of patients had total occlusion ofthe infarct-related vessel.
Working with animal models, Reimer and Jennings et al (17,
18) studied the time course of myocardial necrosis after coronary occlusion. They demonstrated that coronary artery occlusion followed by variable lengths of ischemia and then by reperfusion resulted in predictable degrees of myocardial necrosis.
This myocardial necrosis proceeds from the subendocardial to
the subepicardial layers ofthe myocardium in a wavefront of necrosis in atime-dependentmanner. Early reperfusion occurring
within minutes of occlusion ofthe vessel resulted in minimal to
no myocardial necrosis, whereas reperfusion occurring later in
the time course resulted in a variable amount of subendocardial
necrosis.
Initial human studies with thrombolytic agents utilized intracoronary administration of streptokinase (SK). In 1979, Feit and
Rentrop (19) demonstrated reestablishment of distal blood flow
after administration of SK directly into the coronary thrombus.
Anderson et al (20) studied 50 patients and demonstrated that
intracoronary SK administered at 2.7 hours after the onset of
symptoms resulted in a seven-point difference in ejection fraction (EF) and thus significant myocardial salvage compared to
patients with acute MI who received roufine CCU care. Khaja et
al (21) studied 40 patients who received intracoronary SK at an
average of 4.8 hours afterthe onset of symptoms of acute MI. No
improvement was seen in EF compared to the control group.
The difference in improvement in EF in the Anderson (20) and
Khaja (21) studies was mainly due to a significant difference in
time to treatment (2.7 versus 4.8 hours). The Westem Washington randomized trial demonstrated that intracoronary SK administered within the first 6 hours of the onset of symptoms reduced 30-day mortality rates. This benefit persisted at one-year
postinfarction when intracoronary SK had resulted in total coronary reperfusion (8,22).
Emergency cardiac catheterization and coronary angiograms
involve significanttimedelay, usually about 90 to 180 minutes.
Many hospitals are not equipped for cardiac catheterization and
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so this mode of therapy is available to few patients with acute
Ml. Thus, medical research has focused on the intravenous (IV)
administration of thrombolytics.
The Intravenous Streptokinase in Acute Myocardial Infarction study found that patients treated within 1.5 hours ofthe onset of symptoms had significantly shorter time to peak creatinine kinase (CK) interval, smaller area under CK-MB curve,
and higher global or infarct-related regional EEs compared to
patients treated within 1.5 to 4 hours after acute Ml (23).
Fine et al (24) found that IV thrombolytic therapy administered within 2 hours of symptoms in patients with acute anterior wall MI resulted in smatier infarct size compared to patients
treated within 2 to 4 hours fromtimeof symptoms.
Gruppo Italiano per lo Studio della Streptochinasi nell'
Infarto Miocardico (GISSl), a multicenter, placebo-controlled,
randomized trial, also utilized IV SK (25). This study conclusively showed a reduction in overall mortality of 18% in patients
treated with IV SK compared to patients who received routine
CCU care. Patients treated within 3 hours of the onset of symptoms had a 23% reductton in in-hospital mortality. In patients
who received IV SK within 1 hour of the onset of symptoms, the
in-hospital mortality was reduced by 47% compared to the control group. This survival advantage persisted at one-year followup.
Thus, IV thrombolytic therapy given to patients with acute
MI appears to lyse the occluding thrombus, reestablish perfusion to the ischemic myocardium, and prevent or limit myocardial necrosis in atime-dependentmanner. The "golden period"
appears to be the first 2 to 4 hours after the onset of symptoms,
during which maximum benefit could be achieved from thrombolytic therapy as indicated by reduction in mortality and preservation of residual LV function.

Interventional Delays in Thrombolytic Therapy
The optimal goal of thrombolytic therapy in acute MI is to
administer the thrombolytic agent at the earliest fime, within
minutes if possible, and most certainly within the first 2 to 4
hours of the onset of symptoms. Unfortunately, only a small
proportion of patients receive thrombolytic therapy within this
fime frame (27-29).
The causes of delay in initiating thrombolytic therapy are
multifactorial and include: 1) patient delay in recognizing acute
MI symptoms and seeking medical help; 2) EMS delays in responsetime,on-scene time, and transport time; and 3) delays in
the Emergency Department (ED).
Patient delay
Investigations in patient recognition and responsetimeshave
revealed that up to 44% of acute MI patients do not seek medical
assistance until more than 4 hours after the onset of symptoms
(30). Older patients and those from lower socioeconomic groups
wait longer prior to seeking medical help (31). Only 30% to
50% of patients with acute Ml activate EMS; the remainder use
other means of transport and walk in to the ED (32). The most
common reason for delay in seeking medical care is patient denial. Other reasons include mistaking symploms of acute Ml for
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more benign medical conditions, being alone at home at time of
symptom onset and thus being unable to activate EMS, and attempting to contact personal physician first (33). Limited public
awareness campaigns conducted in Sweden (34) and America
(35) have failed to produce significant increases in the number
of Ml patients who present early for medical treatment. To be effective, public awareness programs need to be of longer duration and repeated frequently.
EMS delay
The EMS "response time," or time from system activation to
EMS arrival at the patient's side, averaged about 8 minutes in
one multicenter study (36). Difficult access to the pafient due to
physical barriers at the scene can contribute to long response
times (37). Also, there are limitations due to weather and traffic
conditions.
The "on-scene time" is the time from EMS arrival at the patient's side until transport is initiated. This time involves evaluation of patient by history and physical examination, electrocardiographic data acquisition, insertion of IV lines, base station
contact with a controlling physician, and initial in-field therapies. In a review of eight major prehospital study groups,
Kereiakes et al (36) demonstrated an average on-scene time of
26 minutes for patients with chest pain.
The EMS "transport time," time from initiation of patient
transport to arrival in the ED, averaged 13 minutes in a multicenter urban study. In rural areas transport times can be much
longer especially if aeromedical transport is not available.
Emergency Department delay
Once the patient suffering from an acute MI arrives in the ED,
whether conveyed by EMS or private transport, rapid diagnosis
and administration is fraught with delays. Factors contributing
to the delay include registration and collection of demographic
data, triage by a nurse and initial physician evaluation, IV access, collection of blood, ECG and a chest x-ray, consultation
with the patient's private physician or cardiologist, and acquisition of the thrombolytic agent from the pharmacy. Sharkey et al
(38) reported an average 20-minute wait after arrival in the ED
before the initial ECG was obtained, and an additional 70 ± 40
minutes before thrombolytics were administered.

Prehospital Thrombolytics
Thrombolytic therapy in the setting of an acute Ml can reduce mortality and morbidity, but its effectiveness is inversely
related to time (10,25). Maximum benefit of thrombolytic therapy is achieved when it is administered within 2 to 4 hours ofthe
onset of symptoms (10,25). Significant time delay to treatment
could be prevented if thrombolytic therapy could be initiated by
the first trained medical team to come in contact with the patient.
In the prehospital setting, this would be either paramedic-staffed
EMS or physician-staffed MCCU. Several studies have focu.sed
on the feasibility, safety, and effectiveness of prehospital administration of thrombolytics in acute MI.
Koren et al (39) studied the use of IV SK in the prehospital
setting. The MCCU physician was able to obtain and interpret
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an initial ECG in the field and begin thrombolytic treatment
with IV SK. The average time from onset of symptoms to treatment was 1.7 ± 0.8 hours. Patients who received treatment in the
first 1.5 hours of symptom onset, versus those who received
treatment between 1.5 and 4 hours of symptom onset, had a significantiy higher global LVEF (56% + 15% versus 47% ± 14%)
and infarct-related regional EF (51 % ± 19% versus 34% ± 20%).
Weiss et al (26) showed similar results with prehospital
thrombolytics using IV SK. Thetimefrom onset of symptoms to
administration of IV SK averaged 63 ± 19 minutes in the field
compared to 114 ± 54 minuies for a similar group of acute MI
patients who received IV tbrombolyfics in-hospital. This study
also showed smaller infarct size and better residual EF in the
prehospital SK group compared to the in-hospital SK group.
Roth et al (40) studied recombinant tissue-type plasminogen
activator (rt-PA) use in acute MI in the prehospital MCCU (n =
74) and in-hospital (n = 44) setting and found prehospital use of
rt-PA safe and feasible. However, this study failed to show significant clinical advantage of prehospital administration of rtPA over in-hospitalrt-PAadministrafion (time to treatment = 94
± 36 minutes versus 137 ± 15 minutes).
Applebaum et al (41) used IV SK in 13 patients suffering
from acute Ml in the prehospital setting using a MCCU. In this
study, patients waited 33 ± 17 minutes after onset of acute MI
symptoms to call the ambulance. Ambulance arrival time was 5
+ 3 minutes. An additional 32 minutes were required before IV
SK therapy was initiated. Thus, time from onset of acute MI
symptoms to initiation of thrombolytic therapy averaged 66.7
minutes. No major complications were noted. A reduction in
time delay of 30 to 60 minutes was achieved by prehospital use
of thrombolytics. These investigators concluded that prehospital thrombolytic therapy is safe and reducestimedelay to treatment.
Castaigne et al (42,43) conducted a two-part study to determine the feasibility and safety of prehospital thrombolytics and
whether prehospital thrombolytics caused delay in the patient's
arrival to the hospital. Phase 1 of the study evaluated the diagnostic accuracy of MCCU physicians. Of the 294 patients evaluated and judged as having unstable angina or acute MI in the
field. 282 were confirmed in the hospital with a low false-positive rate (12 of 294). Of the 62 patients determined to be candidates for thrombolytics in the field by the MCCU team, all cases
upon arrival at the hospital were confirmed as candidates for
thrombolysis by the in-hospital leam. Phase II of this study was
a randomized, placebo-controlled trial. Patients who were diagnosed in the field as having acute MI (n = 100) received either anisoylated plasminogen streptokinase activator complex
(APSAC) (n - 57) or placebo (n = 43). Patients who received
placebo in the field received APSAC upon arrival in the hospital
if indicated. APSAC was given in the field with a median time
delay of 131 minutes after the onset of acute MI symptoms
whereas the median time delay to in-hospital administration of
APSAC was 180 minutes. Thus, there was an average savings of
50 minutes in the prehospital group. No difference was observed
in the complication rate in each treatment group regarding arrhythmias, hypotension, hemorrhage, or death. In-field administration of APSAC did not delay patient arrival to the hospital.
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However, this study failed to show any difference in the early
post APSAC EF in the two groups. This study demonstrates that
prehospital thrombolytic use is feasible and safe and significantiy reduces time delay to treatment.
In the above studies, all ambulances/MCCUs were staffed by
physicians. Physicians evaluated the patients on the scene, obtained and interpreted ECGs, initiated thrombolytic therapy,
and managed complications. In the United States, prehospital
care is rendered by highly trained paramedics. The question then
arises as to whether specially trained paramedics working in collaboration with physicians can safely initiate thrombolytic therapy in the field.
With the ability of transmitting 12-lead ECGs from the field
to a base hospital where a physician can interpret the ECG and
make decisions regarding in-field thrombolysis, prehospital
thrombolytic therapy has become a real possibility.
Cellular ECG equipment can provide hard copies of the 12lead ECGs to the paramedic as well as to the physician at the
base hospital. At the same time, the paramedic can relay pertinent patient medical history and other information to the physician. Based on all of the previous data, the base physician then
decides whether thrombolytic therapy should be begun in the
field. Grim et al (44,45) demonstrated the feasibility and accuracy of cellular telephone transmission of a 12-lead ECG from
the transporting ambulance to the hospital. Aufderheide et al
(46) demonstrated that paramedics were able to obtain prehospital ECGs 94.6% of the time (157 of 166 eligible patients). The
paramedic-performed ECGs required one-third the time of that
needed to perform ECGs in the ED (8.4 + 5.1 minutes versus
24.2 + 21.6 minutes). The prehospital ECGs increased on-.scene
time by an average of 5.2 minutes compared to a retrospectively
evaluated group of paramedic-transported patients (26.8 ± 7.8
minutes versus 21.6 ± 7.6 minutes). There was a high concordance between prehospital and ED 12-lead ECG diagnosis
(99.3% for acute MI and 92.8% for angina). This study also
demonstrated that prehospital 12-lead ECGs were diagnostic in
54.2% of all acute MI patients with a specificity of 99.2% and
positive predicfive value of 92.8%. These values far exceed
those achieved by paramedics using single-lead telemetry (positive predictive value 32.7%).
Grim et al (47) demonstrated that emergency physicians can
accurately make the decision to administer thrombolytic therapy in the field based on the 12-lead ECG and historical information provided by the paramedics. However, only 4.2% of patients evaluated for chest pain (2 of 48) were actually candidates
for in-field thrombolysis.
Several studies have shown that the acquisition of the prehospital ECGs and their transmission to base hospital and protocoldriven assessment of history, physical examination, and risk
factors for administration of thrombolytic therapy do not increase either on-scene or transport fime (14,48). Grim et al (47)
reported an average time from arrival at the scene to arrival at
the hospital of 28 ± 6 minutes in the prehospital ECG group
compared to 27 + 6 minutes in the control group withoul prehospital ECG. The Field Ambulance Study of Thrombolysis in
Myocardial Infarction demonstrated a significant decrease in
the average time delay to initiation of thrombolyfic therapy in
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the hospital by prehospital ECGs (48 ± 12 minutes with prehospital ECG compared to 68 ± 29 minutes for pafients without prehospital ECGs) (48). Thus, prehospital acquisifion of ECG with
either its transmission to the base hospital or by presenting the
12-lead ECG upon the pafient's arrival to the ED can significantiy reduce ED time delay to thrombolytic therapy without increasing EMS on-scene or transport time.
Using strict criteria for the diagnosis of acute MI of I) 1 mm
ST elevation in contiguous ECG leads, 2) "reciprocal" ST depression of at least 0.5 mm in at least one ECG lead, and 3)
an interpretive comment suggesting "injury" or "infarction,"
O'Rourke et al (49) demonstrated lhat paramedic diagnosis of
acute MI was feasible and accurate without telemetry, provided
that patients with prior Q wave infarctions were excluded.
The actual administration of thrombolytic therapy in the preho.spital setting, either on-scene or during transport, has reduced
average time delay to treatment by 30 to 86 minutes (31,40,48).
SK, rt-PA, and APSAC all have been studied in the prehospital
setting and show no reduction in safety or efficacy (32). Initial
studies were conducted using continuous IV infusion of SK.
Castaigne et al (42) have suggested APSAC for use in the prehospital setting since the single IV bolus dose obviates the need
of continuous infusion. Purvis et al (50) and McKendall et al
(51) have demonstrated high (exceeding 90%) infarct artery patency rate on coronary angiograms performed 90 minutes after
an initial bolus of rt-PA. The more common complicattons of
hypotension and reperfusion arrhythmias are usually self-limited and easily treated in the field by the paramedics (52).
Of the 2,472 patients prospectively evaluated for chest pain
during phase I of the Myocardial Infarction Triage and Intervention (MITI) trial, 677 (27%) had clinicalfindingssuggestive of
acute MI (53). Of the 522 patients in whom in-field ECGs were
obtained, 107 were eligible for prehospital thrombolytic therapy
based on diagnostic changes of acute MI on ECG. Thus only
107 (4.2%) of the 2,472 chest pain patients evaluated were potenfial candidates for prehospital thrombolytics. The Cincinnati
Heart Project also showed a low accrual rate of acute MI patients
with only 20 (4.2%) acute Mis identified out of 477 patients
evaluated for chest pain (54). In the Nashville prehospital rt-PA
trial, only three (3.5%) of the 85 patients were found to be actual
candidates forrt-PAin the field over a six-month period (54).
Studies to date have conclusively shown reduction in time delay to treatment of 30 to 70 minutes with prehospital thrombolytics. However, data on clinical benefit from thisfimesaving
is not clear. Randomized trials of prehospital thrombolytics
have shown improved survival without improved residual LV
funcfion (55), improved LV funcfion with no difference in survival (43), and no difference in survival or LV function (56).
Data from the MITI and European Myocardial Infarction Project (EMIP) trials which are currently in progress will hopefully
yield a more definitive answer regarding whether reduction in
fime delay to treatment of 30 to 70 minutes by prehospital
thrombolytic therapy translates into improved survival and improved residual LV funcfion. Phase 11 of the MITI trial, which
began in October 1988, is a prospective evaluation of the benefit
of paramedic administration of rt-PA (53). A total of 800 patients will be randomized lo receive rt-PA in the field or in the
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hospital after prehospital diagnosis of acute MI by 12-lead
ECGs. LVEFs will be measured to judge the benefit of prehospital versus in-hospital thrombolytic therapy. The main goal of
EMIP, a prospective, double-blind, randomized, multicenter intemational study, is to evaluate the benefit/risk ratio of prehospital thrombolytic therapy compared with in-hospital thrombolysis, with total mortality as the major endpoint. Patients suspected of having acute MI receive APSAC in the field or in the
hospital. The goal is to include 10,000 pafients in this study.

Barriers to Prehospital Thrombolytics
About half of all patients suffering from acute M l activate
EMS while the others arrive in the ED by other means of transport (42% in Seattie, 44% in Minneapolis, and 57% in Goteborg) (38,32,35). Thus prehospital administration of thrombolytic therapy would reach only half of all patients with acute MI.
Due to adherence to strict inclusion and exclusion criteria for
prehospital thrombolytics, only about 4% of patients evaluated
for chest pain would be candidates for prehospital thrombolytics
(53). This would translate into few prehospital thrombolytic
treatments given. Gibler et al (54) noted a decline in paramedic
skill because of infrequent use of thrombolytic therapy. Thus it
would be necessary to train paramedics to give thrombolytics in
the field and then periodically retrain them to prevent decline in
their skills. The cost of equipping the ambulance with electrocardiographic and communication equipment may be prohibitive. The costs of stocking the thrombolytic agents in the field
and wastage of these agents due to expiration or breakage may
also be excessive. There could be additional medicolegal risk
for the ED physicians as well as the paramedics due to faulty diagnosis from inaccurate history and increased complicafions.
Interference with cellular telephone transmission could delay
prehospital thrombolysis.

Conclusion
The time-dependent efficacy of thrombolyfic therapy in
acute MI has revitalized interesi in the prehospital care of acute
MI. Thrombolytic therapy within 2 to 4 hours of symptom onset
is desirable. Patient delay in seeking medical attention and low
usage of the EMS system is a major component in delay to
thrombolytic treatment, with as many as one-half of patients
waiting 4 or more hours before seeking medical attention. Inhospital time delay to thrombolytic treatment of 60 minutes is
common despite enhanced general awareness, transfer of responsibility for initiating thrombolytics to the emergency physicians, and stocking of thrombolytic agents in the ED. The acquisition of prehospital 12-lead ECG has been shown to reduce
hospital time delay to thrombolytic therapy in acute MI patients.
Potential time savings of 30 to 60 minutes have been observed
with this strategy. Prehospital diagnosis of acute Ml using 12lead ECG has been found to be feasible and accurate. The use of
all three current forms of thrombolytic agents (SK,rt-PA,and
APSAC) in the prehospital setting is feasible and safe and reduces time delay to treatment. However, clinical benefit from
this reducfion in time delay has not been conclusively shown.
Low public use of EMS, few patients meeting criteria for in-
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field thrombolysis, the high cost of equipping the ambulance
and training paramedics, along with increased medicolegal risks
may make prehospital administration of thrombolytics impractical at the present time. We await the results from ongoing studies of large numbers of patients to help answer this question.
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